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patients compared to non-NDRI patients indicate that
NDRI results in statistically signiﬁcant increases in both
direct and indirect costs to the employer.
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OBJECTIVES: To explore the possible comorbidities
associated with Overactive Bladder (OAB), and to esti-
mate the resource utilization pattern and cost of OAB 
in a Medicaid population. METHODS: A retrospective
case-control matching study was performed. Five thou-
sand ﬁve hundred seven continuously enrolled Medi-Cal
patients who were diagnosed with OAB and received
OAB prescriptions from 1999 to 2001 were 1 :2 matched
based on age, gender, race, and residence county. Annual
hospital utilization and cost were calculated for both
OAB and matched control cohorts, and prevalence ratios
(PR, OAB over control) for 34 ICD-9 based comorbidity
measures from AHRQ were examined. RESULTS: Out of
34 comorbidities, 13 occurred in OAB patients at least
twice as much as in general Medicaid population: paral-
ysis (PR = 10.46), urinary track infection (UTI, PR =
3.74), other neurological (PR = 2.79), peripheral vascu-
lar disorder (PR = 2.42), valvular disease (PR = 2.32),
arrhythmias (PR = 2.31), atopic dermatitis (PR = 2.19),
blood loss anemia (PR = 2.14), depression (PR = 2.10),
pulmonary circulation disorder (PR = 2.10), hypothy-
roidism (PR = 2.08), peptic ulcer disease including bleed-
ing (PR = 2.08), and deﬁciency anemias (PR = 2.05).
Among these diagnoses, obesity, UTI, dermatitis and
depression are known comorbidities related to OAB.
OAB patients had much higher annual resource utiliza-
tion than the matched control group: physician ofﬁce
encounters (27.39 vs. 2.70, P < 0.0001), and an emer-
gency room visits (0.26 vs. 0.04, P < 0.0001). OAB
patients had approximately two-fold higher costs than the
control cohort for pharmacy and medical services:
$3319.85 vs. $1560.06 (P < 0.0001), $4754.86 vs.
$2592.68 (P < 0.0001). CONCLUSIONS: OAB patients
who received drug treatment incurred a heavy economic
and resource burden to the California Medicaid program.
Comorbid conditions were much more prevalent in the
OAB cohort than in the general Medicaid population.
PRK6
A RETROSPECTIVE CLAIMS ANALYSIS OF THE
DIRECT COSTS OF STRESS URINARY
INCONTINENCE
Long S1, Kinchen K2, Orsini LS1, Crown W1, Swindle R2
1The Medstat Group, Inc, Cambridge, MA, USA; 2Eli Lilly and
Company, Indianapolis, IN, USA
OBJECTIVE: To evaluate direct expenditures associated
with urinary incontinence and overall medical expendi-
tures incurred by women diagnosed with stress urinary
incontinence (SUI). METHODS: This is a Retrospective
analysis of administrative claims data. We identiﬁed
women with a diagnosis of SUI in 1996–1999 and no
stress, urge or mixed urinary incontinence diagnoses in
the prior year. We compared total expenditures as well 
as urinary-incontinence-related expenditures for the year
before and after the initial SUI diagnosis. We also com-
pared expenditures for SUI patients receiving surgical
treatment to those who did not. RESULTS: Patients who
met eligibility criteria totaled 8126. Mean annual total
expenditures and UI-related expenditures for all SUI
patients in the year following initial SUI diagnosis were
$9147 (SD $12,434) and $1,382 (SD $2,758) respectively
(15% of total expenditures). The predicted annual total
expenditures and UI-related expenditures for surgical
patients were $13,081 (SD $5,015) and $3,905 (SD
$1134) (30% of total expenditures). Among women with
no comorbid urinary diagnoses, approximately 10%
($733; SD $1,992) of total mean regression-adjusted
annual expenditures ($7,075; SD $12,594) were attrib-
utable to UI. Predicted total expenditures for surgery
patients without comorbid urinary diagnoses were
$13,018 (SD $6,234), 31% of which ($4,056; SD $1,519)
were for UI-related costs. CONCLUSIONS: After diag-
nosis, annual expenditures for patients were roughly
twice that in the year prior to diagnosis. Multivariate
analysis suggests that in the year after SUI diagnosis, UI
treatment costs represented approximately 10–15% of
total expenditures for all SUI patients, and 30–31% of
total expenditures for the subset of surgically-treated
patients.
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OBJECTIVES: The costs associated with kidney trans-
plantation are substantial, not only because of trans-
plantation surgery but also due to the life-long need for
immunosuppressive medication to prevent graft rejection.
We analyzed the economic consequences of the use of 
the two baseline immunosuppressants, tacrolimus (Tac)
and cyclosporin (CyA), currently administered in clinical
practice. METHODS: A retrospective economic analysis
was performed from a hospital perspective in Italy, Spain,
and Germany. The analysis was conducted on the ITT-
population comprising 557 patients from 7 European
countries. Thus, the clinical and medical resource infor-
mation for the pharmacoeconomic analysis was pooled
multi-country data, the cost data was country speciﬁc.
